Clinical Trials Logo

Neurocognitive Dysfunction clinical trials

View clinical trials related to Neurocognitive Dysfunction.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03863639 Terminated - Pre-Eclampsia Clinical Trials

Changes in fMRI and Neurocognitive Function in Women With Pre-eclampsia

Start date: July 7, 2014
Phase:
Study type: Observational

This is a pilot study assessing fMRI changes and neurocognitive function in women with pre-eclampsia and healthy controls. Neurocognitive testing will be done during pregnancy and after delivery up to 2-6 weeks postpartum. fMRI will be done after delivery up to 2-6 weeks postpartum. The aims of this pilot study are therefore to 1) Determine the frequency and nature of co-morbid DTI white matter patency and fMRI functional connectivity changes in women with pre-eclampsia/eclampsia and 2) Determine the relationship between DTI white matter patency and fMRI functional connectivity changes to measurable alterations in cognitive function in this patient population. The aims of this pilot study are therefore to 1) Determine the frequency and nature of co-morbid DTI white matter patency and fMRI functional connectivity changes in women with pre-eclampsia/eclampsia and 2) Determine the relationship between DTI white matter patency and fMRI functional connectivity changes to measurable alterations in cognitive function in this patient population.

NCT ID: NCT03163277 Terminated - Hiv Clinical Trials

Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)

(MARAND-X)
Start date: May 15, 2017
Phase: Phase 4
Study type: Interventional

Neurocognitive disorders are still highly prevalent in the HAART era; despite a dramatic reduction in dementia cases, 15-50% of patients may develop mild or asymptomatic neurocognitive disorders (HIV-associated neurocognitive disorders, HAND). Among other hypothesis neurotoxicity of antiretrovirals has been postulated but its impact is unknown. Our hypothesis is that using drugs with reduced in vitro neurotoxicity may improve cognition in HIV-positive patients withHAND. 76 patients with HAND will be randomized to either continue their treatment or switch to emtricitabine, darunavir/cobicistat, maraviroc. Patients will be re-tested 6 months later.